Yüklüyor......
Systemic treatment for metastatic prostate cancer
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...
Kaydedildi:
| Yayımlandı: | Asian J Urol |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Second Military Medical University
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/ https://ncbi.nlm.nih.gov/pubmed/31061802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|